Response rates in a key group shrink from 62% to 39% as the company blames a “clerical error”.
ApexOnco Front Page
Recent articles
What similarly acting projects are still unpartnered?
A July meeting with the FDA could determine whether Agenus’s bot-bal combo has a shot at a 2024 filing.
The young company’s eighth licensing deal brings in two RAS-targeting projects from Joyo.
The conference’s abstract drop features ASC4First in its plenary session.
An early study of the group’s anti-CD47 project SL-172154 has seen waning efficacy, a heart attack and a death.
Plenty of questions remain about the latest palazestrant data drop as investors hope for a Novartis buyout.
The company scraps its lead project and clears out its C-suite, but there was already a precedent.
